5M Ventures

5AM Ventures is an investment firm funding and building next-generation life sciences companies. It employs a venture capital strategy, investing in early-stage private therapeutic companies, typically Series A. A public equity strategy covers later-stage private and public biotech firms. Its 4:59 Initiative incubates breakthrough science, partnering with academics and entrepreneurs for initial proof-of-concept financing.

Founded in 2002 by John D. Diekman, PhD, and Scott M. Rocklage, PhD, 5AM Ventures recognized the critical need for specialized capital and scientific expertise in early life science innovation. Their combined backgrounds in research and investing established a hands-on philosophy, guiding discoveries into successful therapeutic companies.

The firm supports academic innovators, entrepreneurial teams developing new scientific solutions, and its life science portfolio companies. 5AM Ventures' mission is to catalyze significant healthcare solutions through advanced scientific breakthroughs. It aims to contribute to global health by fostering transformative therapeutic entities.